Artal Group’s Applied Therapeutics APLT Stock Holding History

Artal Group’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,009,500	Closed	-$4.71M	–	8
2024 Q2	$4.71M	Hold	1,009,500	–	–	0.12%	59
2024 Q1	$6.86M	Buy	+1,009,500	New	+$4.53M	0.17%	54
2023 Q1	–	Sell	-400,000	Closed	-$304K	–	120
2022 Q4	$304K	Hold	400,000	–	–	0.02%	120
2022 Q3	$372K	Hold	400,000	–	–	0.02%	128
2022 Q2	$379K	Hold	400,000	–	–	0.02%	129
2022 Q1	$844K	Hold	400,000	–	–	0.04%	127
2021 Q4	$3.58M	Hold	400,000	–	–	0.1%	116
2021 Q3	$6.64M	Hold	400,000	–	–	0.15%	101
2021 Q2	$8.31M	Hold	400,000	–	–	0.17%	97
2021 Q1	$7.5M	Buy	400,000 +20,000	+5%	+$431K	0.13%	112
2020 Q4	$8.36M	Hold	380,000	–	–	0.18%	92
2020 Q3	$7.89M	Buy	+380,000	New	+$9.88M	0.19%	83

Other funds holding APLT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Artal Group's APLT Position: Q3 2024 in Review

Artal Group sold out of Applied Therapeutics (APLT) in Q3 2024, closing a stake of 1,009,500 shares — an estimated $4.71M sold.

Artal Group first reported a position in APLT in Q3 2020 and held it in 12 quarters. The position peaked at $8.36M in Q4 2020. 126 funds tracked by Wall St. Rank hold APLT as of Q3 2024.

Artal Group reported no remaining Applied Therapeutics position as of Q3 2024 after selling out during the quarter.
Artal Group sold 1,009,500 Applied Therapeutics shares in Q3 2024, an estimated $4.71M.
Artal Group first reported a position in Applied Therapeutics in Q3 2020 and held it in 12 quarters.
Artal Group's Applied Therapeutics position peaked at $8.36M in Q4 2020.
126 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.